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Flushing and locking of intravenous catheters are thought to be essential in the prevention of occlusion. The clinical sign of an
occlusion is catheter malfunction and flushing is strongly recommended to ensure a well-functioning catheter. Therefore fluid
dynamics, flushing techniques, and sufficient flushing volumes are important matters in adequate flushing in all catheter types. If
a catheter is not in use, it is locked. For years, it has been thought that the catheter has to be filled with an anticoagulant to prevent
catheter occlusion. Heparin has played a key role in locking venous catheters. However, the high number of risks associated with
heparin forces us to look for alternatives. A long time ago, 0.9% sodium chloride was already introduced as locking solution in
peripheral cannulas.More recently, a 0.9% sodium chloride lock has also been investigated in other types of catheters.Thrombolytic
agents have also been studied as a locking solution because their thrombotic effect was suggested as superior to heparin. Other
catheter lock solutions focus on the anti-infective properties of the locks such as antibiotics and chelating agents. Still, the most
effective locking solution will depend on the catheter type and the patient’s condition.
1. Introduction
Flushing and locking have been strongly associated with
the prevention of catheter occlusion. The causes of catheter
occlusion might be thrombotic, related to drug or par-
enteral nutrition (PN) precipitates or mechanical. Throm-
botic obstruction is caused by an intraluminal clot or a
catheter tip thrombus. Precipitates might be formed by drug
mixtures with an extreme pH, calcium phosphate crystals,
or lipid deposits. Examples of mechanical obstruction are
sleeve formation resulting in partial or total embedding of
the catheter tip, a catheter tip abutting the vein wall, a pinch
off, a kinked or twisted catheter or tubing, tight sutures,
or an incorrect Huber needle placement [1]. However these
mechanical occlusions are extraluminal causes of obstruc-
tion. Flushing and locking maneuvers will not impact these
types of occlusion. On the contrary flushing and locking
are strongly associated with intraluminal occlusion following
build-up of deposits of fibrin and/or infusion fluids (like
PN and dextrose) or a mixture of incompatible medications
and solutions (Figures 1 and 2). Adequate flushing and
locking might also eliminate all potential nesting material for
microorganisms and thus also reduce the risk of catheter-
related bloodstream infection (CRBSI) [2].
The aim of this paper is to clarify issues related to flushing
and locking and to describe the available evidence relating
to the benefits of interventions in relation to occlusion. All
types of intravenous (IV) catheters are considered apart
from apheresis and haemodialysis catheters and catheters in
neonates due to the specific context of these devices.
2. Definition
In this context of rinsing the catheter, flushing of an IV
catheter is defined as a manual injection of 0.9% sodium
chloride or so called normal saline (NS) in order to clean
the catheter. Locking is defined as the injection of a limited
volume of a liquid following the catheter flush, for the period
of time when the catheter is not used, to prevent intraluminal
clot formation and/or catheter colonization. Traditionally, an
anticoagulant, such as diluted heparin, is used. Generally,
flushing and locking are described ambiguously in guidelines
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Figure 1: Visible adhesions to the catheter wall.
Figure 2: Build-up of deposits of fibrin and/or infusion fluids
and/or drug precipitates.
and in the scientific literature which leads to confusion
and misunderstanding. Moreover, flushing and locking are
terms that are mutually exchanged [3–5]. The clinical sign
of occlusion is malfunction. Catheter malfunction is any
condition where, at least, injection or aspiration is no longer
easy but has become difficult or impossible [6].
3. Flushing
3.1. Flushing Technique. Important aspects related to flushing
are syringe diameter and injection flow dynamics. Tradition-
ally, syringes with at least a diameter of 10mL are recom-
mended for long-term central venous catheters. However,
this issue arises only when force applied meets resistance.
Flushing with a small syringe diameter or with high force
applied to the plunger in cases of resistance increases the
risk of catheter damage [7]. This is particularly true in
silicone rubber catheters like tunnelled catheters which have
a lowermaterial strength than polyurethane ones [8]. In these
types of catheters, weak spots originate when catheters are
unintendedly stretched, especially in children. Subsequently,
even an injection with a 10mL-diameter syringe may result
in a catheter rupture. In contrast, most peripherally inserted
central catheters (PICCs) are made of a polyurethane sort of
material and some are even approved for the high pressure
of CT-power injection. Also, almost all totally implantable
venous access devices (TIVADs) or so called ports, in the
marketplace, are power-injectable nowadays [9]. The strict
need to use only a minimum of 10mL-diameter syringes is
redundant if these catheters and portsmaywithstand the high
pressure of power injection.
The dynamic of the injection flow plays a pivotal role in
adequate flushing. Vigier and colleagues showed in a qualita-
tive in vitro study that flushing with an unsteady flow resulted
in a significant reduction of the time scale of deadhesion
of solid deposits compared to flushing with a laminar flow
[10]. This research confirms the promoted practice of using
a so-called push-pause, pulsatile, or turbulent technique to
enhance the rinsing effect in the catheter. Furthermore, based
on physics, not only the flow type but also the time interval
between two boluses is critical for efficient flushing. Indeed,
Guiffant and colleagues filled a catheter lumen with a protein
based liquid albumin in a laboratory setting. Ten mL of NS
was injected under two experimental conditions for catheter
flushing, a laminar, and a pulsed flow. They measured the
amount of recovered albumin from the lumen of the tested
devices. They found that intermittent flushes of 10 times one
mL boluses with a time interval of 0.4 s between two boluses
was more efficient to rinse the catheter than shorter or longer
pauses between two boluses. A continuous low flow infusion
(500mL/24 h) was the less efficient [11]. Therefore, following
IV therapy, even after a continuous infusion of a 1000mL of
NS, a manual flush of 10mL is recommended. No RCT was
foundwhich investigated the effectiveness of this intermittent
flush versus a laminar injection flow technique.
3.2. Flushing Volume. An adequate flush volume is needed to
be able to remove debris and fibrin deposits in the catheter
and port reservoir. Recommendations state the following:
“use at least twice the volume of the catheter and add-on
devices” [3], and then the controversial words follow, “usually
5–10mL” [4]. It is clear that 5–10mL is a much higher volume
than twice the catheter volume. However, especially in long
catheters such as PICCs and tunnelled catheters a larger
volume than 5mL might be necessary to rinse the catheter.
This is also the case in TIVADs because TIVADs consist of
a catheter and a port reservoir. The reservoir has a dead
space and a larger inner volume than a standard catheter.
Adherence of lipid, fibrin, and other drug deposits to the
reservoir wall may result in colonization of microorganisms
and subsequently in CRBSI. Therefore in TIVADs, culturing
the reservoir is more sensitive than the catheter tip if port-
related infection is suspected [12, 13]. Furthermore, inade-
quate flushing might result in debris accumulation in the
reservoir, so called sludge [14]. Clearing the chamber requires
a sufficient flushing volumewhichmay vary depending on the
flow rate and the port type [15]. Ten mL of NS is commonly
assumed as an adequate flushing volume in IV catheters.
However, Guiffant and colleagues found in their in vitro study
that even after a pulsatile flush with 10mL a 100% removal
of the proteins was not obtained [11]. In particular viscous
products are more difficult to remove from the catheter wall.
Indeed, a higher risk of early catheter-related infection was
found when blood products and PN were administrated
through long-term IV catheters [16]. Based on these findings
a flush volume of 20mL is suggested after infusion of viscous
products such as blood components, PN, and contrast media.
Unfortunately, clinical studieswith different flushing volumes
are lacking.
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Table 1: Flushing and locking recommendations.
Flushing recommendations
Technique
Use a pulsatile flow when flushing
Use a flush with 10 × 1mL boluses with a time interval of 0.4 s between 2 boluses
Use SAS and SBS order for the administration of mediation/fluids and blood sampling procedures
Volume Use a 10mL flush for all IV catheters (except for peripheral cannulas, use 5mL)
Use a 20mL flush after infusion of viscous products like blood components, parenteral nutrition, and contrast media
Regimen Flush with NS before and after administration of drugs of fluids (SAS)
Flush with NS before and after blood sampling (SBS)
Locking recommendations
Technique Use the positive pressure technique when disconnecting a syringe
Close clamps and let them closed when not in use
Volume
1.0mL for peripheral cannulas
1.5mL for midlines, PICCs, nontunnelled CVCs, and small bore tunnelled catheters (≤1mm ID)
2.5mL for large bore tunnelled catheters (>1mm ID) and TIVADs (reservoir volume up to 0.6mL, Huber needle
volume not included)
Regimen
q8h–q24h for short-term catheters
Weekly in long-term catheters
q6w–q8w in TIVADs
3.3. Flushing Regimen. Flushing the catheter is the most
important factor in preventing malfunction by maintaining
catheter patency. The fact that fibrin and other deposits are
impeded in attaching to the intraluminal catheter wall is
paramount. Therefore a major recommendation is to flush
before and after administration of medication, also known as
the SAS acronym. The order of IV injections is as follows: a
normal saline flush (S), followed by the administration (A)
of drugs or fluids, followed by a normal saline flush (S). The
use of the similar sequence is even more important for blood
sampling procedures due to the viscous nature of blood: SBS,
a normal saline flush (S), followed by the blood sampling
(B), followed by a normal saline flush (S). If the procedure
ends with a heparin (H) lock the acronym is SASH and
SBSH.The first NS flush provides a clean intraluminal surface
which precludes attachment of drug deposits or fibrin. The
flush at the end of the IV administration or blood sam-
pling procedure prevents accumulation by intraluminal drug
deposits or fibrin and a clean surface impedes attachment
from microorganisms to the inner wall. A 10mL flushing
volume after blood sampling is appropriate because fibrin
contact with the catheter wall is limited to some minutes. In
contrast, after a blood transfusion a flush of 20mL is required
because fibrin might deposit to the catheter wall during a
prolonged time. Similarly, accidental blood reflux into the
catheter and infusion line, for example, when a infusion bag
is empty, requires a manual flush of at least 10mL of NS.
Flushing recommendations that are based on research
and insights are summarized in Table 1.
4. Locking
The goal of an adequate catheter lock is prevention of
premature termination of catheter function by maintaining
patency when the catheter is not in use. The optimal lock
solution prevents clot formation in the catheter and at the
catheter tip, and also prevents microorganism adhesion and
biofilm formation.
4.1. Locking Technique. As far back as in 1987, Shearer sug-
gested using the positive pressure technique to prevent back-
flow of blood into the catheter. This technique was defined
as withdrawing the syringe from the injection site while
still exerting pressure on the syringe plunger when injecting
the last 0.5mL [17]. Alternatively, this could be prevented
by clamping the catheter while injecting the last 0.5mL.
Nowadays, technologies may replace this manual positive
pressure technique such as specially designed syringes with
a plunger rod design (e.g., BD PosiFlush prefilled saline
syringe), neutral or positive displacement connectors, or
valves integrated in catheters (e.g., Groshong catheter, C.R.
Bard).
Although the idea of preventing blood influx at the
catheter tip by the positive pressure technique is reasonable,
some issues arise. This technique prevents only blood influx
at the moment of locking of the catheter. Once the syringe
is removed, other effects might influence the internal volume
such as the clamp thatmight be opened and closed or external
catheter parts that might be pinched. This phenomenon
causes a push out of locking solution and once the pressure
of the pinching/clamping is lifted, the same volume that
has been pushed out will create a backflow of blood at the
catheter tip by negative pressure. From in vitro studies we
know that this pinching also occurs with arm movements in
long catheters inserted in an arm vein. Abduction of the arm
will create a larger catheter volume and generates influx at
the catheter tip. On the contrary, adduction of the arm will
result in a smaller catheter volume and a displacement of
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Table 2: Internal volume of single lumen venous catheters in mL.
Catheter length (cm) Internal diameter (mm)
0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 1.6
10 0.02 0.03 0.04 0.05 0.06 0.08 0.09 0.11 0.13 0.15 0.18 0.20
15 0.03 0.04 0.06 0.08 0.10 0.12 0.13 0.17 0.20 0.23 0.26 0.30
20 0.04 0.06 0.08 0.10 0.13 0.16 0.17 0.23 0.27 0.31 0.35 0.40
25 0.05 0.07 0.10 0.13 0.16 0.20 0.22 0.28 0.33 0.38 0.44 0.50
30 0.06 0.08 0.12 0.15 0.19 0.24 0.26 0.34 0.40 0.46 0.53 0.60
35 0.07 0.10 0.13 0.18 0.22 0.27 0.30 0.40 0.46 0.54 0.62 0.70
40 0.08 0.11 0.15 0.20 0.25 0.31 0.35 0.45 0.53 0.62 0.71 0.80
45 0.09 0.13 0.17 0.23 0.29 0.35 0.39 0.51 0.60 0.69 0.79 0.90
50 0.10 0.14 0.19 0.25 0.32 0.39 0.43 0.57 0.66 0.77 0.88 1.00
55 0.11 0.16 0.21 0.28 0.35 0.43 0.47 0.62 0.73 0.85 0.97 1.11
60 0.12 0.17 0.23 0.30 0.38 0.47 0.52 0.68 0.80 0.92 1.06 1.21
65 0.13 0.18 0.25 0.33 0.41 0.51 0.56 0.73 0.86 1.00 1.15 1.31
70 0.14 0.20 0.27 0.35 0.45 0.55 0.60 0.79 0.93 1.08 1.24 1.41
75 0.15 0.21 0.29 0.38 0.48 0.59 0.65 0.85 0.99 1.15 1.32 1.51
80 0.16 0.23 0.31 0.40 0.51 0.63 0.69 0.90 1.06 1.23 1.41 1.61
85 0.17 0.24 0.33 0.43 0.54 0.67 0.73 0.96 1.13 1.31 1.50 1.71
90 0.18 0.25 0.35 0.45 0.57 0.71 0.78 1.02 1.19 1.38 1.59 1.81
the locking volume. Therefore the authors suggest choosing
catheter material that minimises variation in catheter volume
[18]. Iterative movement of locking volume and blood at the
catheter tip is assumed in catheters inserted in the arm or
catheters with an external part that might be pinched. This
is especially the case in silicone catheters. On the contrary,
silicone catheters have a smaller internal/outer diameter ratio
whereby the volume of displacementwill be smaller thanwith
polyurethane catheters. However the clinical implications of
this phenomenon are lacking; in other words it is unclear
if this will lead to a higher rate of catheter occlusion and
infection. The same phenomenon is observed with increased
intrathoracic pressures in cases of, for example, vomiting,
coughing, and crying. And, in TIVADs, blood influx will
be present when the Huber needle is removed because the
port septum is slightly lifted. This lifting creates a small
influx of blood at the catheter tip. When the needle leaves
the septum, the septum returns to its normal position and.
again, it produces a small positive displacement of locking
solution [19]. Oncemore, the clinical relevance of these fluids
movements at the catheter tip is unknown. Moreover, it is
likely that the use of a heparin lock before needle removal
does not have an added value in, for example, a lower
incidence of malfunction problems. Indeed, in a study on
locking TIVADs with NS or with heparin, the Huber needle
was removed without exerting positive pressure to overcome
the blood influx. No more malfunction was found in the NS
group compared to the heparin group [20]. No studies which
focused on the malfunction rate with versus without the use
of the manual positive pressure technique (without any help
of connectors or valved catheters) have been found.
4.2. Locking Volume. The locking volume must be sufficient
to fill the entire catheter. Therefore the volume of add-ons
might be added to the priming volume of the catheter.
Internal catheter volumes are relatively small: approximately
0.03mL for a peripheral catheter, 0.4mL for a 4 Fr midline,
0.6mL for a 4 Fr single lumen nontunnelled central venous
catheter (CVC), 0.7mL for a 4 Fr PICC, 0.7mL, and 1.5mL
for a small and large bore tunnelled catheter (75 cm), respec-
tively, and 1.3mL for a TIVAD (large reservoir volume of
0.5mL), Huber needle with extension set included.
For trimmed catheters with a circular diameter the
catheter volume might be calculated easily per cm. The
mathematic formula of a cylinder is pi × 𝑟2 × ℎ, whereby
“𝑟” represents the radius (or half of the diameter) and “ℎ”
the height, in our case, the length of the catheter. It is clear
from this formula that the catheter diameter plays a more
dominant role than the catheter length. Table 2 tabulates the
volumes expressed for different internal diameters (ID) of
single lumen catheters. A few examples of available catheters
made of different materials are presented in Table 3. Volumes
can be easily used to calculate the approximate volume of a
trimmed catheter. Note that a difference in catheter length
of 10 cm does not result in a substantial extra lock volume:
0.02mL for a catheter with an ID of 0.5mm (e.g., a single
lumen Hickman 2.7 Fr) and 0.2mL for a large bore catheter
with an ID of 1.6mm (e.g., a 9.6 Fr single lumen Hickman).
For TIVADs the volume of the reservoir should be included
in the total volume. The reservoir volume depends on the
TIVAD brand and is commonly ranging between 0.25mL
and 0.6mL. The priming volume might be provided by the
manufacturers for catheters which may not be trimmed.
The aim of a lock is to fill the catheter entirely. However
the risk of “leakage” of the lock over time has been described
and therefore it is suggested that catheters should be overfilled
by approximately 15–20%. However, this extra volume can
only be recommended if the locking solution does not cause
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Table 3: Examples of corresponding internal and outer diameters in different types of single lumen catheters.
Internal diameter in mm
0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 1.6
Outer diameter in French
Ports, PUR catheters, BBraun 4.5 5 6.5 8.5
Ports, Chronoflex CRBard 6 8.5
Ports, Silicone catheters, BBraun 6.5 8.5 10
PICC, PowerPICC CRBard 4
Tunneled catheter, Hickman CRBard 2.7 4.2 6.6 9.6
Table 4: Calculation of recommended locking volumes if lock does not cause adverse effects when systemically injected.
Catheter type Total lock volume in mL
Minimum catheter volume in mL
(Approximately internal volume + 20%
spillage)
Extra volumea
Peripheral catheters 1.0 0.04 (0.03 + 0.006) 0.9
Midline 1.5 0.5 (0.4 + 0.1) 1.0
PICC 1.5 0.7 (0.6 + 0.1) 0.8
Nontunnelled CVC 1.5 0.7 (0.6 + 0.1) 0.8
Small bore tunnelled catheter (≤1mm ID) 1.5 0.8 (0.7 + 0.1) 0.7
Large bore tunnelled catheter (>1mm ID) 2.5 1.6 (1.3 + 0.3) 0.9
TIVADs (reservoir volume up to 0.6mL) 2.5 1.6 (1.3 + 0.3) 0.9
aVolume might be used for add-ons, Huber needle, extension set extra-long catheters, or surplus for the positive pressure technique.
adverse effects when systemically injected [21, 22]. Still a
20% extra volume is a limited volume, for example, 0.16mL
extra to a locking volume of 0.8mL for the medial lumen
of 18G CVC. The total lock volume for this CVC lumen
is 1mL. In the literature, the reported locking volumes
are significantly larger. However, in current guidelines the
recommended volumes are small (twice the internal volume)
and controversially also large (5–10mL) [3, 4]. Indeed, a 5–
10mL lock volume was found in a survey among ICU nurses
regarding flushing practices for short-term CVCs. Nurses
reported using heparin volumes of 3mL, 5mL, and 10mL
[23]. Consequently, one can state that the injection of a 10mL
locking volume in a short-termCVCwill result in an injection
of 9mL of heparin in the circulation without any residual
effect in the catheter. On the other hand, twice the internal
volume means a locking volume of, for example, 0.06mL for
a peripheral catheter, 0.8mL for a CVC, and for 4 Fr PICC,
1.4mL.
To avoid confusion and given the available variation in
catheter length and diameter, uniform volumes for different
catheter types are suggested. Table 4 shows the calculation for
a more uniform and appropriate catheter lock volume based
on the internal catheter volume (or priming volume) with
an added spillage of 20% and an extra volume (≤1mL) for
add-ons or extra-long catheters. Moreover a small volume
of the locking solution will be left over in the syringe after
manual performance of the positive pressure technique. So
the extra volumemight be necessary especially for nontrained
healthcare workers. A uniform lock volume of 1.5mL is
recommended for all small catheters such as peripheral can-
nulas, midlines, PICCs, nontunnelled CVCs, and small bore
tunnelled catheters. For large bore tunnelled catheters and
TIVADs with a large reservoir, 2.5mL is sufficient. If a strictly
minimum lock volume is recommended, the used volume
should be limited to the internal volume with, eventually, the
20% spillage.
4.3. Locking Regimen. For most low concentration locking
solutions (e.g., a 100U/mL heparin) the lock solution does
not need to be aspirated. When the lock is renewed, the
new locking solution may be instilled without aspiration or
flushing with NS. Some locking solutions, which might be
causing adverse events when injected into the blood circu-
lation, must be first aspirated before renewal for example,
a 5000U/mL heparin lock. Most guidelines recommend
a nonspecified “regular” flush regimen. The optimal time
between two locking procedures when the catheter is not in
use, is not well studied. Commonly a time period between 8
and 24 hours is suggested, although in PICCs and long-term
CVCs periods of 1 week or more are also used.
For TIVADs, when accessing the port for the intermittent
flushing procedure, it is recommended to flush first with
a 10mL NS, before a heparin lock. If the Huber needle
is not correctly located in the reservoir, the paravenous
administration of NS, in contrast to heparin, is not harmful.
There is also a tendency to prolong the interval between
intermittent accesses for TIVAD maintenance from monthly
to every 6 to 8 weeks [24, 25] and even longer time periods
are used. More research is needed to provide scientifically
underpinned answers regarding the best time period to renew
a lock.
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Locking recommendations that are based on research and
insights are summarized in Table 1.
4.4. Locking Solutions
4.4.1. Heparin. A heparin lock was discussed back in the
1970s when IV peripheral cannulas were locked as alternative
to a continuous heparin infusion to keep the cannula patent
[26]. In that time, a lock of 1mL heparin (10U/mL) has been
recommended following each IV injection of medication or
every 8 hours [27]. Since then it also has become clear that
the risks of heparin have to be taken in account. However,
the chance of inducing an iatrogenic haemorrhage following
catheter flushes is rare. The “heparin flush syndrome” has
been described in one case report in which a patient devel-
oped postoperative bleeding after multiple blood samples
and cardiac output determinations, resulting in two to three
flushes of 500 to 1000 units per hour during a 12 hours period
[28]. Heparin has a half-life of 1-2 hours [29]. Given that short
half-life, a catheter lock every 6–8 hours will still be safe for
the patient. Some institutions use a practical guideline to not
exceed the 2000 units per 24 hours. A single dose of 900 units
is approximately 16% of the heparin bolus required to acutely
anticoagulate a 70 kg patient [30].However several other risks
are associated with heparin use. The risk of errors in dosage
of heparin prompted the labelling of heparin as a “high alert”
medication [31–34]. Heparin administration may also lead to
heparin-induced thrombocytopenia and hypersensitivity to
heparin.These are severe adverse effects of heparin even after
exposure to small quantities of heparin from catheter flushing
[35–38]. Moreover an intrinsic risk of heparin is infection
because heparin stimulates S. aureus biofilm formation [39].
Extrinsic risks are the contamination of multiple dose vials
of heparin-saline solution [40, 41] and the risks associated
with breaks in the integrity of the IV system. Heparin is also
associated with drug incompatibilities. Moreover, guidelines
recommend the use of heparin in many different ways
ranging from no heparin but NS as locking solution for
peripheral cannulas to heparin at 10 to 100U/mL for central
venous catheters and TIVADs [3, 4, 42]. For all these reasons,
the use of alternative locking solutions should be considered.
4.4.2. Normal Saline. Discontinuation of heparin as locking
solution seems to be attractive because it eliminates the risks
associated with heparin while it prompt savings in nursing
time, supplies, and costs for the patient and/or the institution
and/or the society. Therefore the hypothesis that there is no
statistical difference for locking a catheter with heparin or
NS has been investigated many times in different types of
catheters. A literature review was conducted to investigate
level I-II evidence [43] relating to the benefits of interventions
on the effectiveness of NS versus heparin as a locking solution
in the prevention ofmalfunction.The results are summarized
for the different catheter types in Table 5.
In peripheral cannulas, evidence was found for the dis-
continuation of the use of heparin locks in twometa-analyses
in the early nineties. In these meta-analyses, studies with
different heparin concentrations, ranging from 2.5U/mL
to 100U/mL, are included [44, 45]. In a more recent
meta-analysis, the evidence was confirmed that there was
no statistically significant difference in duration of patency
or clotting between NS versus a low concentration of hep-
arin (10U/mL) as a locking solution. However, the analysis
showed a higher risk of clotting when locking with NS
versus with a high concentration of heparin (100U/mL) [46].
Since then, 5 randomised controlled trials (RCTs) have been
published with controversial results in a wide variation in
settings, populations, and variables [47–52]. For midlines
no studies which investigated heparin versus NS as locking
solution were found. In nontunnelled short-term CVCs, one
meta-analysis was found. However, it was impossible to draw
conclusions because different heparin volumes, concentra-
tions, and administration routes (IV lock or continuous
infusion or subcutaneously administered) were mixed up in
the analysis [53]. Two RCTs which were published later on
reported mixed results [54, 55].
Although the use of neutral and positive displacement
connectors implies no heparin lock requirement, two RCTs
with PICCs used the locking solution as dependent variable
for occlusion rather than the connector. In the first study a
positive displacement system was combined with the use of
a 10mL NS lock versus 5mL of heparin (100U/mL) [56].
In the second study all PICCs were connected to a neutral
connector and patients were randomised to a 10mL of NS
lock, 5mL heparin 10U/mL, or 3mL heparin 100U/mL lock
[57]. Not surprisingly both studies did not find a statistically
significant difference in incidence of occlusion, probably due
to the investigation of a superfluous use of heparin.
In tunnelled catheters, one RCT with a small sample size
found no difference in nonpatency between a twice daily flush
with 5mL heparin (10U/mL) versus a weekly flush of 9mL
NS [58]. In TIVADs one single RCT investigated the patency
rates between TIVADs locked with heparin (100U/mL) and
NS. No difference in malfunction rates was found [20].
We can conclude that the use of a heparin lock at a
concentration of 10U/mL does not have any added value over
the use of a NS lock in peripheral cannulas. The available
scientific evidence regarding the efficacy ofNS versus heparin
(100U/mL) locking in all types of catheters is weak due to the
limited available methodological rigorous studies.
The use of the positive pressure technique might avoid
blood influx at the catheter tip when disconnecting a syringe.
This procedure is strongly associated with the knowledge and
skills of the healthcare worker. To overcome this problem,
supporting technologies such as valves incorporated in the
catheter tip (e.g., Groshong, C.R. Bard) or at the catheter
hub (e.g., PASV Technology, Navelyst Medical) have been
developed. The integrated valves in PICCs, tunnelled, and
port catheters are designed to avoid blood influx because the
opening pressure of the valve is higher than the pressures
found in the venous circulation.The valve opens only during
positive pressure (injection) or negative pressure (aspiration).
Needleless connectors with neutral or positive displacement
have also been developed to prevent blood influx at the
catheter tip. The need for a heparin lock is eliminated with
the use of these valves and connectors. Therefore heparin
as locking solution is no longer recommended by the man-
ufacturers of these technologies. Few RCTs with a focus
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Table 5: RCTs and meta-analyses comparing NS and heparin as locking solution.
Authors, year
Evidence regarding
patency with the use of
NS versus heparin
Concentration, volume of
heparin
Volume of NS Frequency Remarks
Peripheral cannulas
Goode et
al. 1991∗ [44]
No statistically
significant difference
2.5, 3.3, 10, 16.5, 50, 100,
132U/mL
Volume NR
NR q8h–q24h
Small number of studies,
variation in methodological
quality
Peterson and
Kirchhoff 1991∗
[45]
No statistically
significant difference 1–5mL, 10 to 100U/mL
1–5mL q8h, q12h,
q24h
Small number of studies, few
pediatric studies, variation in
methodological quality
Randolph et al.
1998
∗ [46]
No statistically
significant difference
10U/mL
Volume NR
NR q6h, q8h, q12h Small number of studies
Lower patency rate in
NS group
100U/mL
Volume NR
NR q6h, q8h Small number of studies
Gyr et al. 1995
[47]
Lower patency rate in
NS group
10U/mL
Volume NR
NR q1h–q8h Pediatric population
LeDuc 1997 [48] No statisticallysignificant difference 3mL 10U/mL
3mL 0.5 h–24 h Pediatric population inemergency department setting
Niesen et al. 2003
[49]
No statistically
significant difference 1mL 10U/mL
1mL q12h
Pregnant woman in emergency
department setting, limited
statistical power
Mok et al. 2007
[50]
No statistically
significant difference
(1) 1mL 1U/mL
(2) 1mL 10U/mL
1mL q6h, q8h Pediatric population
White et al. 2011
[51]
No statistically
significant difference 1mL 10U/mL
3mL q8h Pediatric population, smallsample size
Bertolino et al.
2012 [52]
Lower patency rate in
NS group 3mL 100U/mL
3mL q12h Large medical population
Midlines
No evidence available
Nontunneled short-term CVCs
Rabe et al. 2002
[54]
Lower patency rate in
NS group (1) 0.5mL 5000U/mL
(2) 0.5mL q48h
(3) Third arm was Vit C
200mg/mL, 10mL
0.5mL of locking solution was
injected after each check for
blood return without proper
flushing in between
Schallom et al.
2012 [55]
No statistically
significant difference 3mL 10U/mL
10mL q8h
ICU and medical ward, limited
statistical power, ICU and
medical ward
PICCs
Bowers et al. 2008
[56]
No statistically
significant difference 5mL 100U/mL
10mL q12–24h
A positive displacement
connector was used in the 3
groups, small study
Lyons and Phalen
2014 [57]
No statistically
significant difference
(1) 5mL 10U/mL
(2) 3mL 100U/mL
(3) 10mL q12h A neutral connector was used inthe 3 groups, home care setting
Tunneled catheters
Smith et al. 1991
[58]
No statistically
significant difference 5mL 10U/mL
9mL q12h
q7d NS
Small sample size, paediatrics,
onco-hematology patients
TIVADs
Goossens et al.
2013 [20]
No statistically
significant difference 3mL 100U/mL
10mL
Heparin at
discharge or
q8w
Onco-hematology patients
∗Meta-analysis, NR: not reported.
8 Nursing Research and Practice
on catheter patency and locking with heparin versus NS
with the help of these technologies (valves and connectors)
are available. Two RCTs compared valved catheters versus
nonvalved catheters. A first study fromHoffer and colleagues
found a statistically significant lower occlusion rate in valved
PICCs locked with NS versus nonvalved PICCs locked with
heparin (10mL, 10U/mL) [59]. This was confirmed by a sim-
ilar study in TIVADs which found a statistically significant
lower incidence of malfunction in valved TIVADs locked
with NS than in nonvalved TIVADs locked with heparin
(10mL, concentration not reported) [60]. Obviously, more
large scale studies with different types of catheters are needed
to generate evidence based knowledge regarding the value
of valved technology in avoiding heparin as a catheter lock
solution.
Only one RCT investigated a weekly NS lock with a pos-
itive displacement connector versus a twice weekly heparin
lock with a standard cap in tunnelled catheters in the paedi-
atric onco-hematology population. A lower patency rate was
found with a NS lock and positive displacement connector
than a heparin lock 200U/mL (volume not reported) and
a standard cap. No difference in total catheter dwell time
was found [61]. In three RCTs the connector or catheter
type (valved or not) was chosen as dependent variable for
occlusion and not the type of locking solution. In two of these
studies, a reduction in potential staff confusion was reported
as reason for the uniform lock regimen with heparin. In
the first study, patients were randomised to the TIVAD with
valved catheter or TIVAD with nonvalved catheter group.
All TIVADs were locked with 5mL of heparin (50U/mL).
They found a statistically significant higher occlusion rate
in the valved catheter group, despite the heparin use, than
in the nonvalved group [62]. In the second study, patients
with a PICC were assigned to a negative or to one of the two
types of positive displacement connectors. A heparin lock
(3mL of 100U/mL) was used in all types of connectors. A
statistically significant difference between the three groups
was found [63]. Finally, Khalidi and colleagues randomised
patients with PICCs and midlines to a positive displacement
connector or a standard cap with the use of a heparin lock
(concentration and volume not reported). They found no
statistically significant differences between the two groups
[64]. Results from these fewRCTswhich investigated catheter
patency combined with valved catheters and needleless con-
nectors remain inconclusive.
Finally, three systematic reviews which included all types
of catheters, with or without needleless connectors, valved or
nonvalved CVCs are available. Mitchell and colleagues found
weak evidence that locking with a heparin solution versus NS
reduces the occlusion rate. Due to methodological concerns,
no strong conclusions could be drawn [65]. These findings
were confirmed in two recent systematic reviews [66, 67].
It is obvious that the available studies included different
patient populations, different catheter types with different
locking regimens. Moreover different malfunction defini-
tions are used and although all of these studies had a strong
methodological design a lot of them ended up with small
sample sizes. All these issuesmight explain whymixed results
are found. There is an urgent need for further well-designed
studies using uniform terminology and outcomemeasures to
investigate potential differences inmalfunction rates between
heparin and NS as locking solution for venous catheters. Till
then, the choice to abandon heparin as locking solution is
more one of weighing up advantages and disadvantages.
4.5. Other Anticoagulants than Heparin. Lepidurin is an an-
ticoagulant which acts through direct thrombin inhibition.
Only one small study investigated this locking solution versus
heparin in IV catheters. A lepidurin (100 𝜇g) lock was not
found to be superior to a heparin (100U/mL) lock [30].
4.6. Thrombolytic Agents. Urokinase is a thrombolytic agent
and therefore effective in the treatment of thrombotic occlu-
sion. This fibrinolytic drug may also be used in a more
prophylactic way. Moreover the use of periodic fibrinolytic
therapy was also suggested in the prevention of catheter-
related infectious complications [68]. Three studies have
focused on the comparison between heparin and urokinase as
locking solution with mixed results. Solomon and colleagues
assigned patients with a tunnelled catheter to a heparin
(50U/mL, 5mL) or urokinase (5000U/2mL) lock. They
found that the use of twice weekly urokinase lock was
not more effective in reducing infectious and thrombotic
complications than a heparin lock [69]. Ray and colleagues
randomised patients with a tunnelled catheter between twice
daily heparin locks (10U/mL) and a weekly urokinase lock
(9000U/1.8mL). They found that malfunction rates were
statistically significantly reduced by a urokinase lock com-
pared to a heparin lock. This was confirmed by Dillon and
colleagues who assigned paediatric patients with TIVADs
and tunnelled catheters to either a heparin (100U/mL) or
urokinase (5000U/mL, 1.8mL) lock every twoweeks [70]. No
RCTs were found on the effectiveness of other thrombolytic
agents such as recombinant tissue plasminogen activator
or tissue plasminogen activator versus heparin as locking
solution.
4.7. Antimicrobial and Antiseptic Lock Prophylaxis. Due to
the number of manipulations over time, long-term venous
catheters are prone to breaches in aseptic technique during
the manipulation of the catheters. The intraluminal source
of infection is associated with more prolonged dwell times
[71]. Moreover microbial colonization will produce a biofilm
when there is contact with a biomaterial such as the inner
catheter wall [72]. An antimicrobial lock might be instilled
into the catheter with a long enough dwell time to prevent
colonization andbiofilm formation or to eliminate the biofilm
[73]. The antibiotic lock technique was first described in
1988 for the treatment of catheter-related sepsis without
a tunnel or entry-site infection in tunnelled catheters in
home PN patients [74]. Currently, antibiotic locks consist of
a highly concentrated antimicrobial, often in combination
with an anticoagulant (cefazolin, cefotaxime, ceftazidime,
ciprofloxacin, daptomycin, gentamicin, linezolid, telavancin,
ticarcillin-clavulanic acid, and vancomycin) [75].
A meta-analysis of trials in oncology showed weak scien-
tific proof for effectiveness of antibiotic-based lock solutions
compared to heparin in preventing CRBSI. However, in
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the included studies, the investigated antibiotic locks were
heterogeneous (vancomycin, amikacin, and ciprofloxacin)
and the outcome measurement used was nonspecific (sepsis
and noncatheter related sepsis) [76]. Another systematic
review in oncology patients which focused on the prevention
of Gram-positive catheter-related infections in long-term
CVCs showed a reduction of sepsis. The authors concluded
that further research is needed to identify high risk groups
most likely to benefit [77]. This is in line with the Centers for
Disease Control and Prevention guidelines which state that
antibiotic lock prophylaxis should be reserved for patients
with long term catheters who have a history of multiple
CRBSI despite optimal adherence to aseptic technique [78].
It is known that the use of an antibiotic lock may increase
antimicrobial resistance and may also increase the risk of
toxicity to the patient resulting from leaking or flushing of
the lock solution into the systemic circulation. Moreover it
was found that antibiotic treatment, similar to heparin, can
stimulate biofilm adherence to the catheter surface [39, 79].
Therefore there is an urgent need for alternative nonantibiotic
locks and nonheparin anticoagulants.
Nonantibiotic locks or antiseptics kill bacteria through
physical effects rather than specific biochemical pathways
and may not induce microbial resistance [80]. Donlan de-
scribed different approaches to the control of biofilms on
intravascular catheters with chelating agents, ethanol, and
taurolidine [73]. Chelating agents have the potential to
remove established biofilm (bacteria and fungi). Sodium cit-
rate and ethylenediaminetetraacetic acid (EDTA) are chelat-
ing agents. EDTA is used alone or in combinations with
antibiotics [80, 81].
Ethanol also has the potential to remove established
biofilm (bacteria). A systematic review suggested that a
prophylactic ethanol lock decreases the rates of infection and
unplanned catheter removal and that ethanol lock treatment
appears efficacious in combination with systemic antibiotics.
However the review was based mainly on retrospective
studies [82]. A recent RCT comparing heparin (50U in 5mL)
versus 70% ethanol lock (2 hours dwell time) in hematology
patients with tunnelled catheters failed to show a statistically
significant reduction in central-line-associated bloodstream
infection (CLABSI) rates. However the required number of
included patients was not attained and therefore the lack
of impact on CLABSI rates might be underestimated [83].
The use of ethanol has been associated with adverse events.
Mermel and colleagues described an increased incidence
of systemic side effects, breaches in the integrity of the
catheter, and catheter obstruction. Further large scale RCTs
to assess the safety and efficacy of ethanol lock solutions and
limiting the maximum concentration of ethanol to 28% in
lock solutions are suggested [84, 85]. One newly developed
locking solution has reduced the ethanol concentration in the
locking solution to 20% in combination with 0.01% glyceryl
trinitrate and 7% citrate. This lock showed promising results
in eradicating biofilm in an in vitro test [86].
Taurolidine, a derivative of the amino acid taurine, is an
antimicrobial agent showing a broad spectrum of antimi-
crobial activity against both bacteria and fungi [87, 88]. A
meta-analysis of 6 small studies in patients with different
catheter types and taurolidine concentrations suggest that
taurolidine as locking solution reduces the CRBSI incidence
without obvious adverse effects and bacterial resistance [89].
Abnormal taste sensations were reported in two studies [90,
91].
Some antimicrobial and antisepticlocks are not always
considered as traditional “locks.” They do not fulfill all con-
ditions of the earlier definition that a lock is instilled for the
period of time when the catheter is not in use. Antimicrobial
and antiseptic locks might dwell for a limited time and a
common locking solution, such as heparin, might be utilised
in between.
5. Conclusion
Maintaining patency has always been considered essential for
all types of venous catheters. Flushing with NS is important
and probably the most crucial factor in the prevention
of malfunction. However, evidence on flushing techniques,
volumes, and regimens is lacking.Moreover, also the available
scientific basis for catheter locking with heparin is weak.
Hence, clinical studies with a strong methodological design
and a focus on flushing and locking in relation to malfunc-
tion are urgently needed. Uniform malfunction definitions,
terminology, and measurements should be used.
Meanwhile, more standardised flushing and locking vol-
umes should be used. Flushing volumes should be at least
10mL in order to rinse the catheter sufficiently. Locking
volumes should be minimal and based on the catheter
volume. A maximum of 1mL lock volume surplus is suitable
to safely fill the catheter and any add-ons. For peripheral
cannulas, a high flushing and locking volume of the catheter
is not needed due to the small internal volume of the catheter.
The prevention of CRBSI due to biofilm formation is
an increasingly important issue. For long-term CVCs and
especially in susceptible patients an antimicrobial or antisep-
ticlock must be considered.
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